Ublituximab
Briumvi (ublituximab) is an antibody pharmaceutical. Ublituximab was first approved as Briumvi on 2022-12-28. It is used to treat relapsing-remitting multiple sclerosis in the USA. The pharmaceutical is active against B-lymphocyte antigen CD20.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Briumvi
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Ublituximab
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Briumvi | ublituximab-xiiy | TG Therapeutics | N-761238 RX | 2022-12-28 | 1 products |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| briumvi | Biologic Licensing Application | 2023-01-03 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| relapsing-remitting multiple sclerosis | EFO_0003929 | D020529 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
32 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| B-cell lymphoma marginal zone | D018442 | C88.4 | 1 | — | — | — | — | 1 | |
| Neuromyelitis optica | D009471 | EFO_0004256 | G36.0 | 1 | — | — | — | — | 1 |
| Reactive arthritis | D016918 | EFO_0007460 | M02.3 | 1 | — | — | — | — | 1 |
| Hodgkin disease | D006689 | C81 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | UBLITUXIMAB |
| INN | ublituximab |
| Description | Ublituximab, sold under the brand name Briumvi, is an immunomodulator used for the treatment of multiple sclerosis. It is a CD20-directed cytolytic monoclonal antibody.
|
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 1174014-05-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2108354 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB11850 |
| UNII ID | U59UGK3IPC (ChemIDplus, GSRS) |
Target
Agency Approved
MS4A1
MS4A1
Organism
Homo sapiens
Gene name
MS4A1
Gene synonyms
CD20
NCBI Gene ID
Protein name
B-lymphocyte antigen CD20
Protein synonyms
B-lymphocyte cell-surface antigen B1, B-lymphocyte surface antigen B1, Bp35, CD20, CD20 antigen, CD20 receptor, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1, membrane-spanning 4-domains, subfamily A, member 1
Uniprot ID
Mouse ortholog
Ms4a1 (12482)
B-lymphocyte antigen CD20 (P19437)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 400 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
45 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more